Table 3. Comparisons of PFS for exon 19 deletion and exon 21 Leu-858Arg mutation according to treatment-level Bayesian analysis.
| Gef | 0.76 (0.26-2.20) | 1.63 (0.27-10.40) | 0.56 (0.13-2.23) | 0.70 (0.22-2.23) | 0.68 (0.22-2.15) | 0.41 (0.09-1.80) | 0.67 (0.16-2.95) | 3.19 (1.10-9.82) | 4.18 (0.41-44.40) |
| 1.31 (0.45-3.89) | Erlo | 2.15 (0.44-11.80) | 0.73 (0.13-4.30) | 0.92 (0.26-3.40) | 0.90 (0.26-3.40) | 0.54 (0.19-1.54) | 0.88 (0.15-5.69) | 4.21 (1.99-9.59) | 5.49 (0.61-53.60) |
| 0.61 (0.10-3.67) | 0.47 (0.08-2.26) | Ico | 0.34 (0.03-3.25) | 0.43 (0.07-2.63) | 0.42 (0.06-2.59) | 0.25 (0.03-1.66) | 0.41 (0.04-4.07) | 1.96 (0.46-8.03) | 2.57 (0.56-11.70) |
| 1.80 (0.45-7.48) | 1.37 (0.23-7.84) | 2.95 (0.31-30.60) | Dac | 1.27 (0.21-7.83) | 1.23 (0.21-7.75) | 0.74 (0.09-5.51) | 1.21 (0.16-9.75) | 5.76 (1.91-34.90) | 7.53 (0.51-125.00) |
| 1.43 (0.45-4.46) | 1.09 (0.29-3.86) | 2.34 (0.38-15.40) | 0.79 (0.13-4.88) | Afa | 0.97 (0.23-4.14) | 0.58 (0.11-2.97) | 0.95 (0.15-6.19) | 4.57 (1.46-15.10) | 5.99 (0.57-64.80) |
| 1.47 (0.47-4.50) | 1.12 (0.31-3.86) | 2.41 (0.39-15.90) | 0.81 (0.13-4.85) | 1.03 (0.24-4.31) | Osi | 0.60 (0.11-3.05) | 0.99 (0.15-6.34) | 4.69 (1.50-14.70) | 6.15 (0.57-67.30) |
| 2.47 (0.56-11.30) | 1.87 (0.65-5.33) | 4.06 (0.60-28.70) | 1.36 (0.18-10.90) | 1.73 (0.34-9.23) | 1.68 (0.33-9.23) | Erlo+Bev | 1.65 (0.21-14.20) | 7.90 (2.24-30.00) | 10.30 (0.92-121.00) |
| 1.50 (0.34-6.39) | 1.13 (0.18-6.72) | 2.45 (0.25-25.50) | 0.83 (0.10-6.24) | 1.05 (0.16-6.84) | 1.01 (0.16-6.54) | 0.61 (0.07-4.83) | Gef+Peme | 4.79 (0.76-31.20) | 6.24 (0.41-100.00) |
| 0.31 (0.10-0.91) | 0.24 (0.10-0.50) | 0.51 (0.13-2.19) | 0.17 (0.03-0.99) | 0.22 (0.07-0.69) | 0.21 (0.07-0.67) | 0.13 (0.03-0.45) | 0.21 (0.03-1.31) | Plat | 1.30 (0.16-10.70) |
| 0.24 (0.02-2.47) | 0.18 (0.02-1.63) | 0.39 (0.09-1.79) | 0.13 (0.01-1.95) | 0.17 (0.02-1.76) | 0.16 (0.01-1.76) | 0.10 (0.01-1.09) | 0.16 (0.01-2.44) | 0.77 (0.09-6.16) | WBRT |
Results for exon 19 deletion are shown in blue-colour cells, results for exon 21 Leu 858Arg mutation are in gray-color cells. Comparisons should be read from left to right and the estimate is in the cell in common between the column-defining drugs and the row-defining treatment. For 19 del and 21 L858R mutations, HRs (and 95% CrI) less than 1 favour the column-defining treatment. To obtain HRs for comparisons in the opposite direction, reciprocals should be taken. Significant results are in bold and underscored. Abbreviations: Gef, gefitinib; Erlo, erlotinib; Ico, icotinib; Dac, dacomitinib; Afa, afatinib; Osi, osimertinib; Erlo+Bev, erlotinib+bevacizumab; Gef+Peme, gefitinib+pemetrexed; Plat, platinum-based therapy.